1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,370 | 1,398 | 10:27 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Mo | NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT) | 609 | Business Wire | The SRNT, the world's leading scientific society dedicated to nicotine and tobacco research, publishes the results of the CESTO II study in its reference journal, thereby ensuring their optimal... ► Artikel lesen | |
| 28.07. | NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101 | 242 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces... ► Artikel lesen | |
| 22.07. | NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction | 298 | Business Wire | A €600,000 "Innovation Advance" repayable advance granted by Bpifrance
€600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners... ► Artikel lesen | |
| 03.07. | NFL BIOSCIENCES S.A.: NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan's role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation | 1 | Euronext | ||
| 23.05. | NFL BIOSCIENCES S.A.: NFL Biosciences announces the success of its capital increase capped at €3 million | 2 | Euronext | ||
| 22.05. | NFL BIOSCIENCES S.A.: NFL Biosciences launches a capital increase of approximately €2.2 million | 1 | Euronext | ||
| 12.05. | NFL BIOSCIENCES S.A.: NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction | 1 | Euronext | ||
| 05.05. | NFL BIOSCIENCES S.A.: NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity | 1 | Euronext | ||
| 24.04. | NFL BIOSCIENCES S.A.: Marex Group initiates coverage of NFL Biosciences with a Buy rating | 2 | Euronext | ||
| 11.04. | NFL BIOSCIENCES S.A.: NFL Biosciences presents its 2024 annual results and provides an update on its clinical program | 1 | Euronext | ||
| 24.03. | NFL BIOSCIENCES S.A.: NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction | 1 | Euronext |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering | ||
| AVIDITY BIOSCIENCES | 47,230 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 40,690 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update | Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 69,75 | 0,00 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial | ||
| TARSUS PHARMACEUTICALS | 58,59 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,840 | 0,00 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| TREVI THERAPEUTICS | 7,270 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| NUVALENT | 76,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 44,940 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| UPSTREAM BIO | 20,260 | 0,00 % | Upstream Bio, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,660 | 0,00 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| CG ONCOLOGY | 27,460 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates | - Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - ... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,310 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 13,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen |
Das Unternehmen NFL BIOSCIENCES SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,376 Euro und damit -8,87 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.